Navigation Links
YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
Date:4/11/2008

MISSISSAUGA, ON, April 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that posters describing research conducted on two of its anti-cancer drugs, nimotuzumab and tesmilifene, will be presented at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California.

The first poster, entitled "Pharmacokinetic study of the humanized anti-EGF receptor monoclonal antibody nimotuzumab in infant and adult patients" is scheduled to be presented on Sunday, April 13, 2008, 8:00 am to 12:00 pm. (Abstract #211, Poster Section: 8, Post Board Number: 6, Exhibit Hall B-F, Session: Phase 1 Clinical Trials and Clinical Pharmacology 1/Novel Trial Designs).

The research concluded that there is no interaction between nimotuzumab and gemcitabine. YM's licensee in Europe is currently conducting a Phase II /III randomized trial in patients with advanced pancreatic cancer comparing gemcitabine alone to gemcitabine plus nimotuzumab."

The second poster, entitled "Clustering of anthracycline-containing lysosomes in drug-resistant MCF-7 cells in response to tesmilifene" is scheduled to be presented on Monday April 14, 2008 from 1:00 pm to 5:00 pm. (Abstract # 3223, Poster Section: 28, Post Board Number: 26, Exhibit Hall B-F, Session: Drug Resistance 3: Cell Death).

The research concluded that tesmilifene-induced clinical potentiation of drug cytotoxicity in doxorubicin-resistant (MCF-7(DOX-2)) cells was independent of P-glycoprotein status and associated with clustering of lysosomes around the nucleus. This is a hallmark feature
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., , PHILADELPHIA, Dec. 3 /PRNewswire-Fir...the global specialty biopharmaceutical company, to...voluntary market withdrawal of one lot of the Atte...Daytrana ® . Shire is taking this action beca...ture may not meet their release liner removal spec...
(Date:12/3/2009)..., , NEW DELHI, India, Dec. 3 ...,Chief Science Officer at Shenzhen Beike Biotechno...oke at a conference on High-Risk Diabetic,Foot Car... China,s leading,stem cell research and regenerati...ganized by the Indian Podiatry Association (IPA), ...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire/ ...search report is available in its catalogue: ,,...ective ,, http://www.reportlinker.com/p016436...ective.html ,, Incubators are the most critic...r, research, and other applications for providing ...
(Date:12/2/2009)..., , TUSTIN, Calif., Dec. 2 /PRNewswire...sdaq: PPHM ) today reported completion of patient...rial of Cotara® in patients with relapsed gli...brain cancer. Cotara is a targeted monoclonal ant...a potential new treatment for GBM. Cotara specifi...
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5
...sdaq: FOLD ) will announce third quarter 2008 fin...on Monday, November 3, 2008. The results,announcem... webcast that,afternoon at 5 p.m. ET., Interested...nce call at,5 p.m. ET by dialing 877-419-6591 (U.S...honic replay of the call will be available for,sev...
...Eastern Time Today to D...st,Pharmaceuticals, Inc. (Nasdaq: BCRX ) today an... intravenous (i.v.) peramivir, a neuraminidase,inh... or potentially,life-threatening influenza. The Ph...ve days of therapy with either 200 mg i.v. peramiv...
...tivities, enhancement in research investment from ...of user-friendly products is likely to propel the ...tic and manual, to reach $315 million by 2015. , ...B) October 27, 2008 -- Titration is one of the mos...he chemical composition of laboratory and industri...
Other Biology Technology:Amicus Therapeutics Announces Third Quarter 2008 Results Release Date 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 3BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 4BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 6Titrators Market to Reach $315 Million by 2015, According to New Report by Global Industry Analysts, Inc. 2Titrators Market to Reach $315 Million by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:12/3/2009)...olar panels that repels grime and dirt? Expanded b...r? New Tel Aviv University research, just publishe...gh in assembling peptides at the nano-scale level ... in just a few years. , Operating in the range o...) and even smaller, graduate student Lihi Adler-Ab...
(Date:12/3/2009)... a personality change in warmer water, according t...change may make some species more aggressive. , ...n Australia,s Great Barrier Reef have shown for th...tently timid, or consistently bold, and that these...ter temperatures rise. , A slight lift of just o...
(Date:12/3/2009)...ists from the U.S. Department of Energy,s (DOE) Br...and the Indian Institute of Science has made a maj...genetic information in DNA that is necessary to ca...ch, published in the December 1, 2009 edition of ...hat many proteins responsible for interacting at s...
Breaking Biology News(10 mins):A window that washes itself? 2Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease 4733 1Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease 4733 2Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease 4733 3Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease 4733 4Long Term Care 3A The Next Big Womens Issue 3F 51873 1Long Term Care 3A The Next Big Womens Issue 3F 51873 2Sinovac Adjourns 2008 Annual General Meeting 13056 1Sinovac Adjourns 2008 Annual General Meeting 13056 2
... The General Services Administration (GSA) has cer... a provider of Personal Identity Verification (PIV...managed services, under Homeland Security Presiden...on, ABBTECH will offer services through their GSA ...n approved service provider. Services provided b...
...l 3, 2009 -- By identifying a novel compound that ... Ridge National Laboratory and the University of C...stant plants. , In a paper published in Science ...artment of Energy,s ORNL reports that azelaic acid...abidopsis, a small flowering plant related to cabb...
...itor of Playboy magazine, has won the 2009 Media A...ces (AIBS), given to a journalist for outstanding ...r broadcast journalism. Rowe,s story, "Sexual Male... the magazine on scientists, findings during the p...lopment. This segment of the series appeared in th...
Other Biology News:ABBTECH Staffing Services Certified by GSA as an HSPD-12 Managed Service Provider 2Researchers discover primer to plant defense system 22009 AIBS Media Award 22009 AIBS Media Award 3
...98C679.2.1] to Presenilin 2 Alzheimer's disease (... carry mutations in the presenilin proteins (PSEN1...hese disease-linked mutations result in increased ...n component of amyloid deposits found in AD brains...
CryoPlus Square Rack, CP-13-2-CW/100, 27-11/32" OAH from Thermo Scientific
Goat Anti-Human Glypican 2 Polyclonal Antibody, Biotin Conjugated from R&D Systems
Beta 2-Microglobulin ELISA Kit from Biomeda Corporation
Biology Products: